Microbix Addresses Cybersecurity Incident

MISSISSAUGA, Ontario, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is addressing a cybersecurity incident relating to a ransomware attack that has had no impact on operations but involved the theft of data. Microbix is actively addressing the incident, which highlights the importance of the Company’s ongoing program to strengthen its cybersecurity.

An international hacker group, responsible for hundreds of attacks on manufacturing and life sciences companies around the world, penetrated and corrupted a Microbix corporate server with ransomware. Microbix successfully recovered that server and its data without any material disruption to operations. While file storage systems were temporarily offline, no operational, safety, or communications systems, including emails, are believed to have been affected.

However, it has come to Microbix’s attention that at least some company data held on the server was copied externally. Files on the server included commercially-sensitive information and employee data that might be used by hackers for further cybercrime attempts. Hence this news release notification to encourage ongoing vigilance by Microbix customers, employees, investors, and suppliers.

Microbix has been upgrading its software and related IT security systems since early 2022, including the successful implementation of state-of-the art and cloud-based Enterprise Resource Planning (ERP) and electronic Quality Management System (eQMS) software. Concerning cybersecurity directly, Microbix continues to upgrade its systems, including but not limited to the following actions:

• Adoption of Center for Internet Security (CIS) frameworks for its cybersecurity programs.
• Comprehensive, company-wide, and regular employee cybersecurity training.
• Endpoint server protection, for real-time threat monitoring, detection, and response.
• Regular, redundant, and off-line backups of critical information, including cloud information.
• Ongoing work on IT-related and broader disaster-recovery and business-continuity planning.
  

Corporately, Microbix has taken the policy decision that it will not pay ransoms or engage with hackers. This decision is driven by distrust of the integrity of such persons and not wanting to encourage such international criminality by making it financially rewarding.

Microbix’s CEO & President, Cameron Groome, commented “Microbix regrets any impacts of international cybercrime and is continuing to improve its IT security at all levels. We appreciate the understanding of all stakeholders as Microbix, like so many targeted companies, adapts to increasing frequency and sophistication of cyber threats.”

About Microbix Biosystems Inc.
Microbix creates proprietary biological products for human health, with over 120 skilled employees and revenues targeting C$ 2.0 million or more per month. It makes and exports a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) and reference materials (QUANTDx™) supporting POCT & clinical lab EQA, enabling assay development and validation, or helping ensure the quality of clinical diagnostic workflows. Its antigens drive the tests of approximately 100 diagnostics makers, while QAPs or QUANTDx are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides IVDR-compliant CE marked products.

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (e.g., its DxTM™ for patient-sample collection). Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada.

Forward-Looking Information
This news release includes “forward-looking information,” as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, discussion of cybercrime, cybersecurity, and related matters or consequences, Microbix’s goals or objectives, products or services, business and business results, goals or outlook, risks associated with financial results and stability, development projects such as those referenced in its corporate presentation, regulatory compliance and approvals, access to and sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity and timeliness of delivery), currency exchange rates, maintaining profitability and adequate working capital, or raising further capital on acceptable terms or at all, and other similar statements about anticipated future events, conditions or results that are not historical facts. These statements reflect management’s current estimates, beliefs, intentions, and expectations; they are not guarantees of future performance. Microbix cautions that all forward-looking information is inherently uncertain and that actual performance may be affected by a number of material factors, some of which are beyond its control. Accordingly, actual future events, conditions, and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent Microbix’s judgement as of the date of this new release, and it is under no obligation to update or alter any forward-looking information except as required by applicable law.

Please visit https://microbix.com or www.sedarplus.ca for recent Microbix news and filings.

For further information, please contact Microbix at:

Copyright © 2025 Microbix Biosystems Inc.
Microbix®, DxTM™, Kinlytic®, QAPs™, and QUANTDx™ are trademarks of Microbix Biosystems Inc.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.